Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
1. Histone modifications in diseases
Section I Targeting histone modifications for cancer treatment
2. HDAC inhibitors in cancer therapy
3. HAT inhibitors in cancer therapy
4. Targeting DOT1L for mixed-lineage rearranged leukemia
5. BET mechanisms in cancer
6. Histone demethylase inhibitors and their potential in cancer treatment
7. Targeting chromatin remodelers in urological tumors
Section II Targeting histone modifications for infectious disease
8. The therapeutic potential of epigenetic manipulation during infectious diseases
9. Targeting histone deacetylases for bacterial infections
10. Targeting histone epigenetics to control viral infections
Section III Targeting histone modifications for treating other pathologies
11. Targeting histone modifications in psychotic disorders
12. Epigenetic treatment of neurodegenerative diseases
13. Histone modification as a potential preventative and therapeutic approach for cardiovascular disease
14. The potentiality of histone deacetylase inhibitors for diabetes and obesity
15. Targeting histone modifications in cancer immunotherapy
16. Epigenetic drug development for autoimmune and inflammatory diseases
17. Future perspectives for targeting histone modifications in therapy
Histone Modifications in Therapy provides an in-depth analysis of the role of histone mechanisms in major diseases and the promise of targeting histone modifications for disease prevention and treatment. Here, researchers, clinicians and students will discover a thorough, evidence-based discussion of the biology of histones, the diseases engaged by aberrant histone modifications, and pathways with therapeutic potential. Expert chapter addresses the role of histone modifications across a variety of disorders, including cancer, neuropsychiatric, neurodegenerative, cardiac, metabolic, infectious, bacterial, autoimmune and inflammatory disorders, among others. In relation to these disease types, histone modifications are discussed, both as mechanisms of prevention and possible treatment.
A concluding chapter brings together future perspectives for targeting histone modifications in therapy and next steps in research.
- Examines the use of histone modifications in disease prevention and therapy
- Explores the role of histone modifications in cancer, neuropsychiatric, neurodegenerative, cardiac, metabolic, infectious, bacterial, and inflammatory disease, among others
- Features chapters from a broad range of international authors and disease specialists
Clinician-scientists; Human Geneticists; Medical Geneticists; Researchers working in genetics, biology, molecular biology, pharmaceutical science, oncology, cardiology, psychiatry, neurology, neuroscience, metabolic disorders, inflammatory and infectious disease, internal medicine, and clinical therapy; advanced undergraduate students, graduate students; pharmaceutical company and biotechnology researchers interested in drug development and therapies
- No. of pages:
- © Academic Press 2020
- 21st August 2020
- Academic Press
- Paperback ISBN:
- eBook ISBN:
Pedro Castelo Branco completed his doctorate in molecular biology at Oxford University in 2005, followed by post-doctoral fellowships at Harvard University and the University of Toronto. Since 2014 he is a Professor in the Department of Biomedical Sciences and Medicine and head of the Epigenetics in Human Disease laboratory , at the University of the Algarve. His scientific interests include the identification of specific epigenetic signatures throughout carcinogenesis and targeted methylation/demethylation as a therapeutic approach.
Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal; Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal; Algarve Biomedical Center, Campus Gambelas, Faro, Portugal
Dr. Carmen Jerónimo is the Head of the Cancer Biology & Epigenetics Group at the Portuguese Oncology Institute of Porto (IPO Porto) & Invited Associate Professor at the Institute of Biomedical Sciences Abel Salazar - University of Porto. She obtained her PhD in Biomedical Sciences (2001) and Habilitation in Pathology and Molecular Genetics (2011) from the University of Porto. Her PhD project was carried out at Johns Hopkins University (JHU), Baltimore, USA. From 2002 until 2007, she was a Post-doctoral Fellow and Invited Researcher at IPO Porto and JHU (2003). Her current research characterizes the epigenome of tumor cells, through the establishment of the profile of DNA methylation, of histone modifications and alteration patterns of miRNA, of genes related to tumorigenesis and the identification of functional changes involved in the breakdown of cell epigenetic homeostasis. Dr. Jerónimo has authored or co-authored more than 160 international scientific publications, including 4 book chapters and several review articles. She has supervised 3 PhD theses and 30 Master dissertations and collaborated in a patent submission (Methods and biomarkers for detection of bladder cancer US 20130210011/ EP 2630261 A1/ WO 2012052844 A1).
Portuguese Oncology Institute of Porto, Institute of Biomedical Sciences Abel Salazar - University of Porto, Portugal
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.